After rejecting a hostile bid by Sequenom Inc., Exact Sciences Corp. has entered a $24.5 million deal with Genzyme Corp. in a move that could help grow Exact's cancer diagnostics business. (BioWorld Today)

Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today)

Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)